Find publications by Adaptive as well as our collaborators and partners who leverage our technologies.




Neoadjuvant ipilimumab (3 mg/kg or 10 mg/kg) and high dose IFN-α2b in locally/regionally advanced melanoma: safety, efficacy and impact on T-cell repertoire

Tarhini et al.

  • Journal for ImmunoTherapy of Cancer
  • October 2018

Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell

Ruella et al.

  • Nature Medicine
  • October 2018

Acquired cancer resistance to combination immunotherapy from transcriptional loss of class I HLA

Paulson et al.

  • Nature Communications
  • Papers
  • September 2018

Interferon gene therapy reprograms the leukemia microenvironment inducing protective immunity to multiple tumor antigens

Escobar et al.

  • Nature
  • Papers
  • July 2018

Kinetics of intratumoral immune cell activation during chemoradiation for cervical cancer

Dorta-Estremera et al.

  • Biology
  • International Journal of Radiation Oncology
  • Papers
  • Physics
  • June 2018

Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells

Fraietta et al.

  • Nature
  • Papers
  • May 2018

Robust Antitumor Responses Result from Local Chemotherapy and CTLA-4 Blockade

Ariyan et al.

  • Cancer Immunology Research
  • Papers
  • April 2018

ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial

Wrangle et al.

  • Lancet Oncology
  • Papers
  • April 2018

Deep sustained response to daratumumab monotherapy associated with T-cell expansion in triple refractory myeloma

Usmani et al.

  • Experimental Hematology & Oncology
  • Papers
  • February 2018